|
|
Дата |
|---|
| 23:05 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
11.90
|
12.02
|
12.21
|
11.84
|
12.80
|
11.96
|
|
|
2 150 921.61
|
1 620.00
|
|
11.20
|
13.50
|
12.45
|
12.00
|
12.69
|
12.23
|
|
|
2 647 723.34
|
3 265.00
|
|
11.50
|
12.98
|
14.00
|
12.07
|
14.07
|
12.59
|
|
|
2 206 324.30
|
2 015.00
|
|
11.20
|
17.00
|
13.82
|
12.6179
|
14.42
|
13.61
|
|
|
3 607 669.33
|
3 154.00
|
|
11.20
|
17.00
|
13.04
|
12.22
|
14.40
|
13.82
|
|
|
3 887 100.58
|
3 522.00
|
|
12.00
|
17.00
|
12.65
|
12.10
|
13.18
|
12.81
|
|
|
3 497 153.70
|
2 345.00
|
|
11.00
|
13.00
|
12.81
|
11.92
|
13.1499
|
12.40
|
|
|
2 722 326.56
|
3 089.00
|
|
11.00
|
17.00
|
11.52
|
11.47
|
13.075
|
12.44
|
|
|
2 060 950.80
|
1 810.00
|
|
4.78
|
12.02
|
13.11
|
11.25
|
13.11
|
11.76
|
|
|
2 229 198.73
|
2 379.00
|
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company. The Company is focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with unmet medical need. Its lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson's disease (PD). It has the potential to be disease-modified by primarily replacing a patient's lost dopaminergic (DA) neurons with dopaminergic neuron precursor cells (DANPCs). The Company is leveraging its proprietary platform to build a diversified pipeline of autologous iPSC-based therapies for the treatment of multiple CNS diseases, with an initial focus on sporadic and genetic PD.
The Company is also conducting the open-label Phase 1/2a ASPIRO trial of a single dose of sasineprocel in mid-stage to moderately advanced PD patients.
Показать все Скрыть